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The natural course of human immunodeficiency virus (HIV) infection is characterized by high
viral load, depletion of immune cells, and immunodeficiency, ultimately leading to acquired
immunodeficiency syndrome phase and the occurrence of opportunistic infections and
diseases. Since the discovery of HIV in the early 1980s a naturally selected population of
infected individuals has been emerged in the last years, characterized by being infected for
many years, with viremia constantly below detectable level and poor depletion of immune
cells. These individuals are classified as “elite controllers (EC) or suppressors” and do
not develop disease in the absence of anti-retroviral therapy. Unveiling host factors and
immune responses responsible for the elite status will likely provide clues for the design
of therapeutic vaccines and functional cures. Scope of this review was to examine and dis-
cuss differences of the cell-mediated immune responses between HIV+ individuals with
disease progression and EC.
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BACKGROUND
Hallmarks of human immunodeficiency virus (HIV) infection
are the persistent depletion of immune cells, immune dysfunc-
tion, and inflammation, favoring the occurring of opportunistic
infections and illnesses thus disease progression (Douek et al.,
2003; Silvestri et al., 2003). In the natural course of HIV infec-
tion infected individuals are characterized by flu-like symptoms,
rapid decrease of CD4+ T cells, and high viral loads (acute phase
of infection, lasting 2–6 weeks), followed by stabilization of the
number of CD4+T cells and viral load (chronic phase of infection,
lasting years). However, during the chronic phase a slow but con-
stant decrease of the number of CD4+ T cells and increase of viral
load occur. These events are further complicated by the chronic
activation of the immune system, and inflammatory responses,
favoring the occurring of co-morbidities. Arising of opportunistic
infections and diseases is typical of the Acquired ImmunoDefi-
ciency Syndrome (AIDS) phase, as defined when CD4+ T cell
counts drop to <200 cells/µl of blood.
Over than the above described HIV infected individuals,
defined as natural progressors, a restricted set of HIV infected indi-
viduals control infection naturally in the absence of anti-retroviral
therapies. Two main populations have been described based either
on their maintenance of peripheral CD4+ T cell counts for sev-
eral years (long-term non-progressors, LTNP), or on their total or
partial control of HIV viremia (elite controllers, EC).
Long-term non-progressors are characterized by being infected
by more than 7 years, have stable CD4 T cell counts always above
500 cell/µl of blood and stable low but detectable viral loads,
representing approximately 5% of all chronically HIV infected
individuals.
Elite controllers represents a further restricted population
(about 3/1000 of HIV infected individuals) (Deeks and Walker,
2007; Okulicz and Lambotte, 2011), and are defined by stable
CD4 cell count (irrespective of a threshold), anti-retroviral therapy
naïve, and with viral loads persistently below 50 copies/ml (unde-
tectable) for more than 12 months (Okulicz and Lambotte, 2011).
Moreover, some individuals showed both features of LTNP and
control of viral load, and have been defined as “elite LTNP” (for
example,>8 years of HIV infection, CD4 cell nadir≥600µwith a
positive slope of CD4 T cell counts) (Grabar et al., 2009). Indeed,
in most cases, these cohorts of HIV-1+ individuals controlling
disease progression only partially overlap, underlying different
determinants of resistance to HIV-1 disease progression.
Elite controllers are also characterized by very low levels of
viral load in the cerebrospinal fluid (below 2.5 copies/ml), whereas
number of leukocytes and levels of inflammatory markers, such as
albumin, neopterin, CCL2/MCP-1, and interleukin (IL)-10, over-
lap with those of uninfected or highly active anti-retroviral therapy
(HAART)-treated HIV individuals (Probasco et al., 2010). There-
fore, EC have the ability to control viral load both at the systemic
level and in the central nervous system (CNS). These findings
implicate that the virus either does not reach the CNS or that local
immune responses control viral replication, although the lack of
local inflammatory events suggest that a reduced amount of virus
or replication occurred in CNS.
Indeed, control of viral loads in EC is temporary (Bailey et al.,
2007; Goujard et al., 2009; Okulicz et al., 2009), and a durable
control of viremia for more than 10 years occurs only in 1% of the
individuals ascribed to this set of people (Lambotte et al., 2005;
Grabar et al., 2009; Okulicz et al., 2009). Of particular interest is
that AIDS events have been described also in few EC experiencing
drop in CD4+ T cell count despite maintaining undetectable viral
load (Pereyra et al., 2008, 2009; Sajadi et al., 2009). Studying tran-
sition from the EC status to the AIDS phase will provide invaluable
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insights for deeper comprehension of immune mechanisms con-
trolling HIV infection and disease progression, thus for design of
alternative or complementary therapies than HAART.
Therefore, EC represents a unique opportunity for unravel-
ing if and how immune responses are controlling HIV infection.
Indeed, it can be argued that individuals naturally restricting infec-
tion have been in contact with a deficient virus. However, viruses
isolated from EC have replicative capacity as much as laboratory
adapted strains (Migueles et al., 2003; Bailey et al., 2006b; Blank-
son et al., 2007; Lamine et al., 2007), no main viral genetic defects,
or viral polymorphisms are responsible for the spontaneous con-
trol of HIV replication in these persons (Blankson et al., 2007;
Miura et al., 2008), and synonymous substitutions occurs in gag,
pol, and negative regulatory factor (nef) genes as a result of low
level ongoing replication (Miura et al., 2009c; O’Connell et al.,
2010; Salgado et al., 2010). GB virus C has been demonstrated to
inhibit HIV replication in in vitro infected cells (Xiang et al., 2004;
Jung et al., 2005) and in HIV+ individuals persistent co-infection
with GBC virus is associated with prolonged survival (Zhang et al.,
2006); however, it has been reported that frequency of GB virus C
viremia was not different between EC and HIV progressors, thus
not explaining the non-progressive course of disease in this elite
cohort (Blankson et al., 2008).
Moreover, recent study has shown that the virus could be trans-
mitted from a progressor that developed AIDS to an individual
who became EC (Bailey et al., 2008), thus addressing the impor-
tance of host factors in the control of infection. In particular, many
investigators have searched for differences in the humoral and
cellular responses between EC and natural progressors. However,
humoral response, such as titer and breadth of HIV neutralizing
antibody, in EC does not appear to be different when compared
with that observed in natural progressors (Bailey et al., 2006a;
Li et al., 2009b; Mahalanabis et al., 2009; Scheid et al., 2009),
thus excluding a protective role in the early and chronic phase of
infection. In support of these findings it has been reported that rit-
uximab, a monoclonal antibody used as chemotherapeutic agent
for the elimination of B cells in lymphomas, did not modify the
elite status of treated HIV+ individuals, such as viral load below
50 copies/ml (Gaillard et al., 2011), although the same treatment
has been reported with the reactivation of latent HBV and CMV
infections (Aksoy et al., 2007) and increased viral load in chroni-
cally HIV infected (non-elite controller) individual (Huang et al.,
2010).
All these findings tend to support the hypothesis that among
immune responses the cell-mediated pathways might play a major
role responsible for the elite status of HIV+ individuals.
CELL-MEDIATED IMMUNE RESPONSES IN ELITE
CONTROLLERS
HIV AND HLA
Human immunodeficiency virus infection and the viral protein
Nef causes down modulation of human leukocytes antigen (HLA)-
class I molecules (Schwartz et al., 1996) to avoid recognition of
infected cells by cytotoxic T lymphocytes (CTL). On the other
hand, natural killer (NK) cells quickly recognize infected cells
by detecting down modulation of HLA-class I molecules, thus
recognizing viral infected cells very soon after infection. At the
same time, HLA-C and HLA-E are not down modulated upon
HIV infection (Cohen et al., 1999). Thereby, HIV to avoid detec-
tion by CTL encodes mechanisms for removal of class I major
histocompatibility complex (MHC) proteins from the surface of
infected cells, and is protected from NK cell cytotoxicity primarily
by HLA-C and HLA-E.
Well documented correlates of delayed disease progression in
HIV+ individuals controlling viral load in the absence of anti-
retroviral therapy include several alleles of the MHC Class I genes.
HLA-B alleles have been found to be more resistant than HLA-A to
the Nef-mediated downregulation (Rajapaksa et al., 2012), and few
HLA-B alleles reported to contribute to the control of viral load in
HIV+ individuals, as B∗27, B∗57, and B∗14 that have been associ-
ated with efficient poly-functional CD8 response (Almeida et al.,
2007a), viremia control (Fellay et al., 2007), and slow disease pro-
gression (Pereyra et al., 2010; Lazaryan et al., 2011). However, HLA
allele combinations also exert a strong effect on non-progression in
LTNP (McMichael and Jones, 2010; Salgado et al., 2011). Genome-
wide association studies have also indicated genetic variants of
MHC Class I genes (HLA-C) associated with control of viral load
and disease progression through modulation of the response of
CD8+ and NK cells (Fellay et al., 2007; Thomas et al., 2009),
whereas others have highlighted a role of MHC Class I and III sin-
gle nucleotide polymorphisms (SNPs) in determining the LTNP
phenotype (Guergnon et al., 2012).
CD8+ T LYMPHOCYTES
Human leukocytes antigen-B57 and HLA-B27 alleles have been
found to be over-represented among EC (Kaslow et al., 1996;
Migueles et al., 2000; Kiepiela et al., 2004; Lambotte et al., 2005),
and supported by multiple studies showing that HIV-1-specific
CD8+ T cells from EC were qualitatively superior (e.g., high pro-
liferative capacity and cytotoxic activity) to those from patients
with progressive disease (Migueles et al., 2002; Betts et al., 2006;
Addo et al., 2007; Almeida et al., 2007a; Saez-Cirion et al., 2007).
In particular, a poly-functional response to HIV stimulation was
observed for CD8+T cells isolated from EC and LTNP,and was lost
in individuals becoming progressors (Betts et al., 2006; Almeida
et al., 2007a; Streeck et al., 2008). Poly-functional response was
characterized by efficient process of degranulation and release of
perforin and granzyme B, as well as of cytokines IFN-γ, TNF-
α, IL-2, and MIP-1β (Migueles et al., 2002, 2008; Hersperger
et al., 2010). The increased level of poly-functional CD8+ T cells
was inversely correlated with viral load (Betts et al., 2006), and
findings reported in humans have been confirmed in macaques,
showing that depletion of CD8+ T cells in animals controlling
viral load, as the human counterpart EC and LTNP, is associ-
ated with rapid increase of viral load and drop of CD4+ T cell
count (Friedrich et al., 2007). According to this set of informa-
tion, it was reported that transition from LTNP to the progres-
sor status was associated with the acquisition of viral mutations
conferring escape from CD8+ T cell responses (Kemal et al.,
2008), and recently confirmed in animal model (Mudd et al.,
2012).
It is of interest that EC and HIV+ individuals under HAART
have comparable viral loads but the presence of poly-functional
CD8+ T cells remains a characteristic of EC (Dinoso et al., 2008;
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Ferre et al., 2009; Peris-Pertusa et al., 2010; Lopez et al., 2011),
despite that therapy-treated HIV+ individuals increased the num-
ber of CD4+ T cells (Peris-Pertusa et al., 2010), meaning that this
cellular population is one of the host factors responsible for the
suppression of viral load rather than a consequence of the infec-
tion or exposure of CD8+T cells to high viral loads before therapy
(Lopez et al., 2011).
When CD8+ T cells from LTNP (controlling the viral load,
but with detectable viral load) and progressors (unable to control
viral load) were compared, the authors showed higher levels and
ability to expand of CD8+ T cells when isolated from LTNP vs.
progressors, although no difference between the two cohorts were
observed for the functional properties of CD8+ T cell (expression
of cytokines, such as MIP-1β, TNF-α, and IL-2, upon stimulation
with Gag or Nef peptides) (Lopez et al., 2008). Also these findings
could be interpreted as that host factors, such as CD8+ T cells,
are able to control virus replication independently by exposure
to low/high levels of viral load. Nonetheless HIV-specific poly-
functional CD8+ T cells from EC have recently been described to
be in a differentiation stage of central memory T cells (Lopez et al.,
2011; Ndhlovu et al., 2012) and to be rapidly expandable upon
stimulation with Gag peptides (Ndhlovu et al., 2012). Indeed, it
has also been reported that the control of viral load in HIV+ in the
absence of ARTis mostly associated with HLA-B27-restricted Gag-
specific CD8+ T cells (having stronger avidity, poly-functionality,
and clonal turnover than HLA-A restricted CD8+ T subpopula-
tions) (Almeida et al., 2007a; Berger et al., 2011). It has recently
reported that among the many factors influencing the efficacy of
this protective allele in EC, expression of specific TCR clonotypes
(Chen et al., 2012), and evasion from regulatory T (Treg) cells sup-
pression (Elahi et al., 2011) are features associated with delayed
HIV disease progression.
Recently, it has also been reported that CD8+ T cells of
non-controllers or patients under HAART are characterized by
loss of CD100 expression (alternative name is Sema4D, a sema-
phorin with important immune regulatory functions that improve
antigen-specific priming by antigen presenting cells and also acts as
costimulatory molecule on T cells), whereas EC maintain CD100
expression as much as non-infected individuals (Eriksson et al.,
2012).
Mucosal immunity
Increased magnitude of CD8+ T cell response to HLA-B27
and HLA-B57-restricted Gag epitopes, such as HIV p24Gag and
p17Gag as well as other non-immunodominant epitopes (Ferre
et al., 2009), was reported in both blood and rectal mucosa of EC
(Shacklett et al., 2003; Ibarrondo et al., 2005; Ferre et al., 2009,
2010), and increased level of poly-functional CD8+ T cells in rec-
tal mucosa of EC (Critchfield et al., 2007, 2008; Ferre et al., 2009,
2010) has been proposed as one of the reason why these individ-
uals experience lower depletion of CD4+ T cells than progressive
individuals normally seen in this anatomical compartment of HIV
progressors (Brenchley and Douek, 2008). However, CD8+ T cells
in lymph nodes and gastrointestinal mucosa of infected macaques
express high levels of PD-1, suggesting immune exhaustion (Velu
et al., 2007), and reduced ability to clear chronic infection. These
findings suggest that mucosal CD8+ T cells may be or become
inadequate over time, and possibly linked to the progression from
the elite to the progressor status (i.e., loss of control of viral load).
In conclusion, EC are characterized by preservation of func-
tional CD8+ cells mounting appropriate and strong Gag-specific
response, poly-functional, and at the central memory stage. More-
over, selection for mutated but less-fit viral variants, as consequent
to the immune selective pressure by HLA-I/CD8+T cells, has been
proposed as an additional mechanism for the control of viral load
in elite controller (Miura et al., 2009a,b,c). Indeed, HLA hetero-
geneity and low to undetectable HIV-specific CD8 T cell responses
have been observed among HIV-1 controllers cohorts, with all
the above variants together accounting for approximately 40% of
all individuals with a resistant phenotype to HIV-1 disease (Emu
et al., 2008; Pereyra et al., 2008). It is likely that additional genetic
or immuno-virological determinants of resistance to HIV-1 dis-
ease progression are yet to be discovered (O’Brien and Nelson,
2004). In support of this interpretation is also that selection of
mutated HIV variants is indicative of ongoing viral replication,and
escape from T cell-mediated immunity also occurs in individuals
naturally controlling HIV viral load.
NATURAL KILLER CELLS
A second cellular population showing cytotoxic activity against
virus infected cells is represented by NK cells, potentially con-
tributing to viral control along with traditional adaptive immune
responses in some controller individuals. Recent findings have
shown association between the killer inhibitory receptor (KIR)
alleles and virus control. In particular, KIR3DL1 and KIR3DS1
have been associated with delayed progression to AIDS when inter-
acting with HLA-B alleles. Thus, NK-mediated control of HIV
replication has been also in cohorts of HIV+ individuals with
spontaneous control of viral load (Martin et al., 2002, 2007; Lopez-
Vazquez et al., 2005;Yawata et al., 2006; Alter et al., 2007; Long et al.,
2008; Kamya et al., 2011a). Of note is that HIV controllers express-
ing HLA-Bw4∗80I on target cells and KIR3DL1 on NK cells sustain
a target cell-induced NK cytotoxicity stronger that that measured
for CD8+T cells from the same individuals (Tomescu et al., 2012).
Other than the interaction between HLA-B alleles and KIRs, role
for HLA-C alleles in HIV-1 infection has been recently described.
Genome-wide association studies have indicated that a SNP in the
HLA-C promoter region as an important factor linked with virus
control (Fellay et al., 2007, 2009; Thomas et al., 2009). It is not
clear yet the protective mechanism of HLA-C SNP variant, but it
has been proposed shown that HLA-C SNP variant is associated
with increased expression of both HLA-C transcript and surface
protein (Kulkarni et al., 2011), which correlates with good levels
of CD4 counts, control of viral load, and slow disease progression
(Thomas et al., 2009).
Several authors have also shown that HIV-1 mutation escap-
ing from CTL responses are indeed recognized by NK cells
(Alter et al., 2011; Fadda et al., 2011). However, if this situa-
tion also occurs in HIV+ individuals naturally controlling viral
load, and in particular EC, will be quite difficult to assess. On the
other side, it would be of interest to monitor if viral mutations
influence HLA-mediated antigen presentation and recognition by
CTL vs. NK cells, associated with the lack of the status of elite
controller.
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CD4+ T LYMPHOCYTES
CD4+ T cells, or T helper cells (Th), play a central role in immune
protection, by inducing (i) long-term maintenance of antigen-
specific CD8+ memory T cells, (ii) antibody production from B
cells, (iii) macrophages to develop enhanced microbicidal activ-
ity, to recruit neutrophils, eosinophils, and basophils to sites of
infection and inflammation, and (iv) expression of cytokines and
chemokines to orchestrate the full panoply of immune responses.
Naive conventional CD4+ T cells are open to at least four distinct
fates that are determined by the pattern of signals they receive dur-
ing their initial interaction with the antigen; Th1, Th2, Th17, and
Treg cells (Zhu and Paul, 2008).
The number and functionality of CD4+ T cells constantly
decrease during HIV disease progression, although progressive
impairment and massive deregulation of all players of the immune
system are observed in infected individuals, ultimately leading to
the development of AIDS (Giorgi et al., 1999; Hellerstein et al.,
1999).
In the majority of the EC population, the spontaneous control
of HIV-1 infection is associated with higher levels of CD4+ T cells
(average of 750 cells/ml) than viremic and therapy-treated HIV+
individuals, and slightly lower than uninfected subjects (Hunt
et al., 2008; Hatano et al., 2009; Okulicz et al., 2009; Sedaghat
et al., 2009; Kamya et al., 2011b). Control of the level of CD4+ T
cells in EC has been ascribed to preservation of uncompromised
thymic function in conjunction with extra-thymic processes that
led to elevated levels of circulating recent thymic emigrants (Yang
et al., 2012). However, a small proportion of EC developed declin-
ing number of CD4+ T cells despite undetectable levels of HIV-1
viremia as HIV-1 patients with progressive disease, that was asso-
ciated to reduced thymic output mirrored by thymic dysfunction
during untreated progressive HIV-1 infection (Hunt et al., 2008;
Okulicz et al., 2009; Sedaghat et al., 2009; Yang et al., 2012).
Human immunodeficiency virus infection is characterized
by uncontrolled viral replication and chronic immune acti-
vation, such as increased level of CD4+ and CD8+ T cells
expressing activation markers such as CD38, HLA-DR, and/or
Ki67 expression (Kestens et al., 1994; Liu et al., 1997; Benito
et al., 2005; Almeida et al., 2007b; Hunt et al., 2008). Chronic
immune activation is responsible for the disease progression, as
clearly reported in animal models infected with simian coun-
terpart simian immunodeficiency virus (SIV) (Silvestri et al.,
2003).
Some studies report that despite having undetectable viral
loads, EC had lower levels of immune activation than progressors,
similar levels to that observed in HAART-suppressed individuals,
although higher than uninfected subject (Hunt et al., 2008; Owen
et al., 2010). On the other hand, EC have lower levels of activated
HIV-specific CD4+ T cells than progressors and HAART-treated
individuals (Owen et al., 2010), although maintained stronger
immune response to HIV antigens than progressors, as character-
ized by interferon-γ (IFNγ) and IL-2 expression toward the Gag
protein (Emu et al., 2005; Owen et al., 2010). The capacity to rec-
ognize minimal amounts of the immunodominant Gag293–312
peptide results from high avidity TCR/MHC interaction (Vingert
et al., 2010). This capacity may play a key role in HIV control,
by keeping the immune system in constant alert and allowing
the induction of rapid recall responses. High levels of CD4+IL-
2+INF-γ+ cell phenotype, with a large IL-2 production, is indica-
tive of a robust Th1 response (Migueles et al., 2000; Potter et al.,
2007).
Human immunodeficiency virus-specific CD4+T cell function
is partially restored by HAART-driven control of viral infection,
suggesting that the characteristics of the HIV-specific CD4+ T
cell response in EC, such as Gag responses, might be a conse-
quence rather than the cause of the low viral burden (Tilton et al.,
2007). Therefore, maintenance of good levels of CD4+ T cells and
functional antigen-specific CD4+ T cells in EC might represent
one aspect driving the potent anti-viral activity exerted by CD8+
T cells observed in this cohort of patients. This aspect is sup-
ported by experiments in the animal model of infection, such as
SIV infected macaques. Experimental depletion of CD8+ T cells
in macaques controlling SIV replication lead to a rapid rebound
in SIV viremia, whereas the subsequent recovery of the immune
system was associated with emergence of SIV-specific CD4+ and
CD8+ T cell responses, thus restoring undetectable or low viral
loads (Friedrich et al., 2007).
Members of the CD28 family, such as CD28 and the inhibitory
molecules PD-1 and CTLA-4, contribute to the cell cycle arrest
and termination of T cell activation occurring after TCR/MHC
engagement. Levels of PD-1 and CTLA-4 are higher on CD4+ T
cells of HIV progressors, than uninfected individuals, and correlate
with persistent viremia, disease progression, and lack of cell func-
tionality, such as low IL-2 production from HIV-specific CD4+
T cells in response to viral antigens (Day et al., 2006; Kaufmann
et al., 2007). These characteristics were reported in both acute
and chronic infection, either in untreated or virologically sup-
pressed HAART-treated HIV+ individuals. On the other side, EC
had very low levels of expression of CTLA-4, even lower than
therapy-treated individuals (Kaufmann et al., 2007).
Few studies have addressed the question if CD4+ T cells from
EC might be less susceptible to HIV infection than cells purified
from HIV progressors. The results of these studies are controver-
sial, since some authors suggested that cells from EC were resistant
to infection because of selective up-regulation of cyclin-dependent
kinase inhibitor p21 (Chen et al., 2011), whereas others reported
resistance of EC CD4+ T cells to HIV-1 infection but showed that
p21 plays no or indirect role in this phenomenon (Saez-Cirion
et al., 2011). A third study reported that CD4+ T cells from EC
were as susceptible to infection as CD4+ T cells from uninfected
individuals (Julg et al., 2010; O’Connell et al., 2011).
Other authors searched for differences in the virion budding
from infected cells (i.e., virus spreading). Indeed, it was reported
that chronic progressors produced significantly more virus per
infected cell than cells from EC and uninfected individuals, but
budding from cells of EC and uninfected donors was similar
(O’Connell et al., 2011). The hypothesis is that the higher lev-
els of virus replication from cells of chronic progressors was
a result of differences in the cellular activation level caused by
high-level viremia in the patients and not an innate difference
that would cause specific disease progression (O’Connell et al.,
2011).
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REGULATORY T CELLS
Regulatory T cells have been previously known as suppressor T
cells, as they are a subpopulation of T lymphocytes suppressing
immune responses of other cells. Thus, Treg maintain tolerance to
self-antigens and abrogate autoimmune disease, as mouse models
have confirmed their role in autoimmune and inflammatory dis-
eases, cancer, and organ transplantation (Dranoff, 2005; Battaglia
and Roncarolo, 2011). Tregs are a subset of CD4+T cells expressing
CD25 and Foxp3+, and regulate immune responses by production
of cytokines, including transforming growth factor-β (TGF-β),
IL-10, and IL-35.
The role of this cell population during HIV infection is contro-
versial. It has been proposed that excessive immune suppression by
Treg cells might be responsible for the faster progression on HIV
pathogenesis (Kinter et al., 2007). On the other hand, Treg cells
might protect individuals from the deleterious effects of chronic
immune activation that is typically observed in HIV infection
(Belkaid and Rouse, 2005; Fazekas de St Groth and Landay, 2008).
It has been reported that HIV individuals naturally controlling
viremia, such as EC, or under effective therapy, have lower lev-
els of Tregs compared with progressors, but that all of them have
higher levels of Tregs than uninfected subjects (Brandt et al., 2011).
However, other authors reported a higher levels of Tregs in EC than
in both progressors and individuals under anti-retroviral therapy
with fully suppressed infection (Owen et al., 2010), findings that
were confirmed in the SIV infected macaques (Chase et al., 2007).
Reasons for those discrepancies are unclear but, at least in part,
might be explained by the lack of specific Treg markers, and the dif-
ferent ethnicity of individuals enrolled in the studies. For example,
genetic expression profiling showed that ethnic background plays
a role in the levels of expression of FoxP3, thus in the levels of Treg
cells as based on their classification based on this antigen (Torcia
et al., 2008). Indeed, ethnicity of HIV+ individuals enrolled in the
studies discussed above, although not reported, might be different
in that the two cohorts are based in Denmark and California.
TH17
Activity and expansion of Treg are regulated by a subset of Th
cells, such as IL-17 producing T helper (Th17) lymphocytes. Con-
trary to the Treg cells, Th17 contributes to inflammation and
immune responses to infectious agents, as well as to the main-
tenance of autoimmune diseases (Zhu and Qian, 2012). Th17
cells by the production of IL-22 stimulate epithelial cells (i.e.,
mucosal immunity) to produce anti-microbial proteins to clear
out fungi (Candida) and bacteria by promoting inflammation
through stimulating inflammatory cytokine release, chemokine
expression, and recruitment of neutrophils (Bettelli et al., 2007;
Weaver et al., 2007). Therefore lack of Th17 cells may predispose
the host to opportunistic infections, clinical conditions occurring
also in HIV+ individuals. Overall, Th17 cells act as counterbal-
ance of Treg cells in their ability to control/maintain peripheral
tolerance and immune responses (Coimbra et al., 2012).
As to HIV infections and disease progression, it has been
reported that marked and selective depletion of Th17 cells in
lymphoid organs and mucosal tissue is typical of SIV disease pro-
gression, in that observed only in infected macaques developing
pathogenesis but not in the natural host African green monkeys
that do not develop signs of AIDS or disease progression (Favre
et al., 2009). Therefore, loss of Th17 and disequilibrium with Treg
was associated to SIV disease progression. Findings reported in
animal models have been also validated in HIV infected indi-
viduals, showing that in peripheral blood loss of Th17 cells, and
imbalance of Th17/Treg ratio, is characteristic of disease progres-
sion (Favre et al., 2010; Li et al., 2011). EC maintained levels of
Th17 and Treg, as well as Th17/Treg ratio, similar to that of unin-
fected individuals (Favre et al., 2010; Li et al., 2011). Therefore,
these findings highlight the role of Th17 cells and the relevance of
Th17/Treg ratio imbalance.
Another important aspect to be considered is about the abil-
ity of Th17 controlling microbial infections at mucosal site, as
loss of Th17 might account for the increased microbial transloca-
tion across the gastrointestinal mucosa (Brenchley et al., 2006).
Therefore, strategies aimed at preventing Th17 loss will allow
controlling disease progression mediated by the chronic immune
activation, in part by controlling microbial translocation through
gastrointestinal mucosa.
Therefore, among HIV+ individuals, EC are characterized by
maintenance of good levels of CD4+T cells (including Th17 cells),
low level of activation of CD4+ T cells but strong response of
CD4+T cells to Gag antigens leading to a sustained Th1 phenotype
(CD4+ T cells expressing IL-2 and IFN-γ).
EXTRACELLULAR SOLUBLE FACTORS IN ELITE CONTROLLERS
Cytokines and chemokines are a group of low molecular weight
proteins that mediate communication between immune and non-
immune cells, contributing to regulate development, tissue repair,
hematopoiesis, inflammation, and immune responses (Rossi and
Zlotnik, 2000). They have pleiotropic activities and functional
redundancy, and act in a complex network where one compound
can influence the production of, and response to, many other fac-
tors. Chemotactic cytokines, chemokines,are involved in the traffic
of leukocytes to lymphoid and non-lymphoid organs, as well as
for the recruitment of leukocytes to injury and infection sites,
in metastasis and angiogenesis (D’Souza and Harden, 1996; Rossi
and Zlotnik, 2000; Gerard and Rollins, 2001; Moser and Loetscher,
2001). Apart from the chemoattractive functions, chemokines
modulate inflammatory events, such as activation, costimulation,
and differentiation of T cells and monocytes (Luther and Cyster,
2001; Mackay, 2001; Mellado et al., 2001).
CYTOKINES AND CHEMOKINES
Cytokines and chemokines play important roles in all steps of
HIV life cycle, from the engagement of cellular receptors by HIV
envelope for gaining entry into the target cells to the budding
step (Alfano and Poli, 2001; Alfano et al., 2008). Some cytokines
may limit viral spread whereas others may contribute to its prop-
agation (Cocchi et al., 1995; Vicenzi et al., 2000; Alfano and Poli,
2005), but the cytokine effect is also dependent on the cell phe-
notypes. Indeed, β-chemokines inhibit HIV replication in T cells
but enhances virus replication in macrophages (Schmidtmayerova
et al., 1996).
In vivo studies have shown that EC have equal serum levels of
IP-10, MCP-1, MIP-1α (Card et al., 2012), and IL-21 as uninfected
individuals (Iannello et al., 2010), but higher levels of TGF-β (Card
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et al., 2012). On the other hand, when compared to HIV+ individ-
uals unable to control viral load, EC showed lower levels of IP-10,
MCP-1, and TGF-β, but higher levels of MIP-1α (Iannello et al.,
2010; Card et al., 2012).
MIP-1α is a natural ligand for CCR5 (and CCR1), an HIV core-
ceptor, thus blocking HIV infection through competitive binding
of CCR5 (Cocchi et al., 1995), but also inhibiting post-entry steps
of HIV independent of coreceptor usage (Saunders et al., 2011).
Therefore, elevated level of MIP-1-α have been associated with
resistance to HIV infection and elevated level of this chemokine
has been linked to delayed disease progression (Paxton et al., 1996;
Saha et al., 1998; Hersperger et al., 2010). It is tempting to spec-
ulate that this chemokine might contribute to the control of viral
load and disease progression in EC.
On the other hand, MCP-1 and IP-10 are known positive regu-
lator of HIV replication and increased levels of MCP-1 have been
reported to correlate with negative prognosis (Stylianou et al.,
2000; Ansari et al., 2006, 2011).
As to the anti-inflammatory cytokine TGF-β, it has been
reported that increased levels are associated with disease progres-
sion (Nilsson et al., 2006; Piconi et al., 2010). Therefore, in EC
(vs. progressors) lower levels of TGF-β might be associated with
more favorable prognosis, also due to the fact that TGF-β inhibits
T cell response, and thus in EC low levels of TGF-β might allow
for the strong HIV-specific CD8+ T cell response, thus control of
viral load.
Interleukin-21 is mainly produced by follicular Th CD4+ cells,
and exert pro-survival activity for CD4+ T cells, thus for main-
tenance of HIV-specific CD8+ T cells and of their cytolytic
potential (Zeng et al., 2005), as well as regulator of T cells,
B cells, and NK cells responses during chronic viral infections
(Elsaesser et al., 2009; Frohlich et al., 2009; Yi et al., 2009; Pal-
likkuth et al., 2012). Indeed, IL-21 also promotes differentiation
of naive CD4+ T cells into Th17 cells, which play an important
role in inducing inflammation and controlling invading pathogens
(Wei et al., 2007; Yang et al., 2008). Thus, IL-21 has been pro-
posed as biomarkers of HIV disease progression but also as
one of the target to be exploited for immunotherapy in HIV+
progressors.
DEFENSINS
Defensins are natural antibiotic peptides against bacteria and fungi
(Chang and Klotman, 2004). Defensins are classified on the basis
of their size and pattern of disulfide bond into α, β, and θ cat-
egories (Yang et al., 2002), and are produced constitutively or in
response to microbial products or pro-inflammatory cytokines
(Ganz and Lehrer, 1998; Lehrer and Ganz, 1999; Schroder, 1999).
Cellular source of defensins are neutrophil, NK cells, epithe-
lial, and dendritic cells (Agerberth et al., 2000; Chalifour et al.,
2004; Rodriguez-Garcia et al., 2010), thus locating their beneficial
(i.e., antibiotic) or detrimental [i.e., chronic inflammation-driven
tumors, such as colorectal cancer (Albrethsen et al., 2005)] effects
at mucosal site.
Alpha-defensins have also been shown to inhibit multiple steps
of the HIV life cycle (Zhang et al., 2002; Chang et al., 2003; Mack-
ewicz et al., 2003; Furci et al., 2007; Garzino-Demo, 2007), thus
representing important innate defensive mechanism against HIV
infection at mucosal sites, such as cervico-vaginal tissue (Cole and
Cole, 2008).
It has been recently shown that immature dendritic cells
from EC expressed higher level of α-defensins than progressors
(Rodriguez-Garcia et al., 2009), and that the levels of α-defensins
are independent of viral load, as underscored by the fact that HIV+
individuals under therapy expressed the same levels of α-defensins
as progressors (Rodriguez-Garcia et al., 2009).
CONCLUSION AND FUTURE DIRECTIONS
Studying HIV disease and progression is not an easy task because
of the high rate of mutations occurring in the viral strain, as
well as to the acquired immunodeficiency, chronic immune acti-
vation, chronic inflammation, and the consequent opportunistic
diseases and infections. The existence of individuals naturally
controlling HIV viral load represents a unique opportunity for
understanding mechanisms of the immune system patrolling
viral replication and clearance of infected cells. It appears that
viral genetic defects or humoral responses in EC do not play a
major role controlling HIV viral load, whereas innate responses
have been reported of potential interest. CTL seems to repre-
sent the main cellular phenotype controlling HIV viral load,
although it must be recognized that the in vivo findings are
resulting from a combination of cells and factors influencing
each other.
Thus far the most appealing findings characteristic of EC are
the strong responses mediated by CD8+ T cell and NK cells, and
low levels of inflammatory markers, such as albumin, neopterin,
MCP-1, and IL-10. Relevance of these findings to the prognosis
of HIV disease has been clearly testify in SIV infected macaques,
showing that (i) removal of CD8+ T cells in animals controlling
viral load is associated with rapid increase of viral load and drop
of CD4+ T cell count (Friedrich et al., 2007), whereas (ii) chronic
immune activation and the consequent chronic inflammation is
associated to disease progression (Chahroudi et al., 2012).
Moreover, studies in EC underscore that exposure to low level
of antigen exposure is sufficient to boost and sustain strong and
efficient HIV-specific immunity. However, some EC lose their
ability to control viral load over time, indicating that factors
other than HLA-mediated control contribute to the “elite” sta-
tus. Indeed, even patients virologically suppressed on HAART for
years demonstrate elevated levels of pro-inflammatory cytokines
and chronic immune activation. These clinical events, associated
with the extended survival time upon HAART (Fang et al., 2007),
are associated with the occurring of opportunistic disease and poor
outcomes (Nixon and Landay, 2010).
Indeed, HAART has been provided extreme benefits to HIV
individuals, and intervening on the innate immune responses of
therapy-treated individuals to restore or induce proper effector
functions, as closer as possible to that of EC, is required for
eradication of viral reservoir and elimination of the causes respon-
sible for opportunistic diseases. Boosting proper innate immune
responses will be required for both preventive (Li et al., 2009a)
and the rapeutical strategies (Critchfield et al., 2007, 2008), but
also controlling the chronic status of inflammation will be needed
for reducing the occurring of opportunistic diseases, including
non-AIDS associated tumors.
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Levels of pro- and anti-inflammatory cytokine and chemokines
are usually measured in the plasma of HIV+ individuals and
considered for defining the inflammatory status as consequent
to the chronic immune activation. However, plasma levels of these
factors, especially those not correlated with viremia, would deserve
future attention in order to unveil their functions, such as influ-
encing activity and expansion of poly-functional CD8+ T cells in
EC. Findings from clinical trials based on α1-Antitrypsin (Bristow
et al., 2010, 2012) and IL-2 (Marchetti et al., 2008) have shown that
strategies aimed at the manipulation of the innate immune sys-
tem responses are feasible ways to enhance the control of virus life
cycle (Alfano, 2010). Furthermore, it must be recognized that the
net effect of a soluble factor on cellular phenotypes as well as on
the control of HIV replication is depending by the interaction with
all other soluble factors either in the plasma or in the extracellular
milieu of organs/tissues and associated to the extracellular matrix.
In other words, cell-mediated immune responses are depending on
the localization of immune cells. Therefore, better comprehension
of innate immune responses, and host and viral factors inducing
protective immune responses in EC, particularly at the mucosal
level, might reveal the proper way for the design of a protective
anti-HIV vaccine.
Further studies comparing cohorts of HIV individuals such as
progressors and EC, as well as in animal models, are needed but
will provide invaluable insight for the prevention and control of
HIV disease. In particular, studying modulation of host factors
during transition from LTNP and EC to the progressor status will
be of paramount relevance for establishing conditions associated
to the control of viral load and immunodeficiency.
Unveiling the mechanisms associated with successful HIV con-
trol in EC will contribute to (i) better understand HIV patho-
genesis, (ii) the design of therapies for the control of disease
progression, and (iii) for vaccine strategies (Johnston and Fauci,
2007). In particular, because of the capacity of EC to restrict viral
load below 50 copies/ml, it will be of paramount interest defining
host factors and innate immune responses responsible for the (i)
LTNP and EC conditions, (ii) control of viral load, and (iii) drop
of CD4+ T cell counts.
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